# US 2006/0154958 A1 · Bicyclic heterocycles as cannabinoid receptor modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154958 A1
- Document ID: US20060154958A1
- Status: Published application
- Kind: A1
- Application number: 11/330,657
- Filed: 2006-01-12
- Published: 2006-07-13
- Earliest claimed: 2005-01-12
- Assignees: Bristol-Myers Squibb Company
- Inventors: Richard Sulsky; William Ewing
- Web page: https://patentgrep.com/patent/US20060154958A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/34: Tobacco-abuse
- C07D 487/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R3a, R4, A, B, and n are described herein.

## Claims

### Claim 1

A compound or a pharmaceutically acceptable salt or a stereoisomer according to Formula I:
wherein,
A is selected from the group consisting of CO and SO2;
B is selected from the group consisting of a direct bond, oxygen, NR8 and alkyl;
R1 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and CF3;
R2 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, COOR7 and CONR7R7a;
R3 and R3a are hydrogen or R3 and R3a taken together form a double bond with oxygen;
R4 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
R7 and R7a are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
or R7 and R7a taken together can form cycloalkyl or heterocyclyl;
R8 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
or R4 and R8 taken together can form cycloalkyl or heterocyclyl;
n is an integer of 0 or 1.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein,
A is —S(O)2—.

### Claim 3 (depends on 2)

The compound according to claim 2 wherein,
B is a direct bond.

### Claim 4 (depends on 3)

The compound according to claim 3 wherein,
R3 and R3a are hydrogen; and
n is 1.

### Claim 5 (depends on 4)

The compound according to claim 4 wherein,
R1 is selected from the group consisting of aryl and heteroaryl.

### Claim 6 (depends on 5)

The compound according to claim 5 wherein,
R2 is selected from the group consisting of aryl and heteroaryl.

### Claim 7 (depends on 6)

The compound according to claim 6 wherein,
R4 is selected from the group consisting of aryl and heteroaryl.

### Claim 8 (depends on 1)

The compound according to claim 1 wherein the compound is:

### Claim 9 (depends on 1)

A pharmaceutical composition, comprising:
at least one compound according to claim 1; and
at least one pharmaceutically acceptable diluent or carrier.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, further comprising:
at least one additional therapeutic agent.

### Claim 11 (depends on 1)

A method for treating obesity, comprising administering to a patient in need a therapeutically effective amount of a cannabinoid receptor 1 (CB1) antagonist according to claim 1.

### Claim 12 (depends on 1)

A method for smoking cessation, comprising administering to a patient in need a therapeutically effective amount of a cannabinoid receptor 1 (CB1) antagonist according to claim 1.
